3K3A-APC, an investigational therapy for stroke about to enter Phase 3 clinical testing, may also help to protect the brain against Alzheimer’s disease and other forms of dementia. “Our recent and current data support development of 3K3A-APC for neurological conditions associated with cognitive dysfunction such as Alzheimer’s disease and injury to the brain’s white matter that results in vascular dementia,” Berislav Zlokovic, MD, PhD, said in a press release. Zlokovic is a professor at the…
You must be logged in to read/download the full post.
The post Stroke Therapy Candidate 3K3A-APC Holds Promise for Dementia appeared first on BioNewsFeeds.